International normalized ratio versus plasma levels of coagulation factors in patients on vitamin K antagonist therapy

Archives of Pathology and Laboratory Medicine

Volumn 135, Issue 4, 2011, Pages 490-494

  Gulati, Gene ^a,f   Hevelow, Megan ^b   George, Melissa ^a   Behling, Eric ^a,c,d   Siegel, Jamie ^b,e  

^a Department of Pathology Anatomy and Cell Biology   (United States)

^b Cardeza Foundation for Hematologic Research   (United States)

^c THOMAS JEFFERSON UNIVERSITY   (United States)

^d Department of Anesthesiology   (United States)

^e Bayer HealthCare Pharmaceuticals Inc   (United States)

^f THOMAS JEFFERSON UNIVERSITY HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; BLOOD CLOTTING FACTOR; WARFARIN;

ADULT; AGED; ARTICLE; BLOOD; BLOOD CLOTTING DISORDER; DRUG MONITORING; FEMALE; HUMAN; INTERNATIONAL NORMALIZED RATIO; MALE; METHODOLOGY; MIDDLE AGED;

ADULT; AGED; AGED, 80 AND OVER; ANTICOAGULANTS; BLOOD COAGULATION DISORDERS; BLOOD COAGULATION FACTORS; DRUG MONITORING; FEMALE; HUMANS; INTERNATIONAL NORMALIZED RATIO; MALE; MIDDLE AGED; WARFARIN;

EID: 79955084921     PISSN: 00039985     EISSN: 15432165     Source Type: Journal    
DOI: None     Document Type: Article

References (8)

1. Hirsh J, Guyatt G, Albers GW, Harrington R, Schunemann HJ. Antithrombotic and thrombolytic therapy 8th ed: ACCP guidelines, executive summary. Chest. 2008; 133: 71S-105S.
2. Edmunds LH Jr. Hemostatic problems in surgical patients. In: Colman RW, Hirsh J, Marder VJ, Clowes AW, George JN, eds. Hemostasis and Thrombosis. 4th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2001: 1033.
3. Ageno W, Garcia D, Aguilar ML, et al. Prevention and treatment of bleeding complications in patients receiving vitamin K antagonists, part 2: treatment. Am J Hematol. 2009; 84(9): 584-588.
4. Olsen JD. Answer to the question, "Some of our physicians are frustrated when they are called regarding critical protimes when the international normalized ratio or INR is within therapeutic range. Can I establish our critical/call range by INR instead, and how?" [question and answer section]. CAP Today. September 2008: 111.
5. Ierkeman A, Astermark J, Hedner U, Lethagen S, Olsson C, Berntorp E. Correlation between different intensities of anti-vitamin K treatment and coagulation parameters. Thromb Res. 2000; 98(6): 467-471.
6. Kumar S, Haigh JRM, Boothby M, et al. Effect of warfarin on plasma concentrations of vitamin K dependent coagulation factors in patients with stable control and monitored compliance. Br J Haematol. 1990; 74(1): 82-85. (Pubitemid 20043577)
7. Lind SE, Callas PW, Golden EA, Joyner KA Jr, Ortel TL. Plasma levels of factors II, VII and X and their relationship to the international normalized ratio during chronic warfarin therapy. Blood Coagul Fibrinolysis. 1997; 8(1): 48-53. (Pubitemid 27156099)
8. Sarode R, Rawal A, Lee R, Shen YM, Frenkel EP. Poor correlation of supratherapeutic international normalised ratio and factor levels during warfarin therapy. Br J. Haematol. 2006; 132(5): 604-607.